Screener
TG Therapeutics TGTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Net income | $27,558 | $33,247 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Loss on extinguishment of debt | 9,153 | — |
| Stock-based compensation | 47,825 | 31,333 |
| Depreciation and amortization | 85 | 21 |
| Amortization of premium (discount) on investment securities | (621) | (2,619) |
| Amortization of debt issuance costs | 532 | 608 |
| Amortization of leasehold interest | 91 | 94 |
Document
FAQ
- What is TG Therapeutics's stock-based comp?
- TG Therapeutics (TGTX) reported stock-based comp of $27.88M in Q2 2026.
- How has TG Therapeutics's stock-based comp changed year-over-year?
- TG Therapeutics's stock-based comp increased by 70.4% year-over-year, from $16.36M to $27.88M.
- What is the long-term trend for TG Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), TG Therapeutics's stock-based comp has grown at a 1.4% compound annual growth rate (CAGR), from $61.27M to $64.67M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about TG Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude